Next 10 |
home / stock / bivi / bivi articles
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims...
SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ:BIVI) investors who suffered substantial losses to sub...
NEW YORK, March 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds inves...
PHILADELPHIA, March 14, 2024 (GLOBE NEWSWIRE) -- Berger Montague advises investors that a securities fraud class action lawsuit has been filed a...
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company...
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVi...
Recently completed financing provides sufficient funds for near-term Parkinson's Disease priority Plans for Phase 2b trial of NE3107 as first...
NEW YORK, March 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds inves...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company...
News, Short Squeeze, Breakout and More Instantly...
BioVie Inc. Company Name:
BIVI Stock Symbol:
OTCMKTS Market:
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood brain barrier, could represent a novel oral treatment targeting a...
“Bezisterim” has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioV...
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, to...